This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Benbrook, Doris
| Item Type | Name |
|
Concept
|
Thiones
|
|
Academic Article
|
Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.
|
|
Academic Article
|
High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
|
|
Academic Article
|
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.
|
|
Academic Article
|
Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry.
|
|
Academic Article
|
Development of flexible-heteroarotinoids for kidney cancer.
|
|
Academic Article
|
Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia.
|
|
Academic Article
|
Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.
|
|
Academic Article
|
Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.
|
|
Academic Article
|
NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.
|
|
Academic Article
|
Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs.
|
|
Academic Article
|
Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line.
|
|
Academic Article
|
Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780.
|
|
Academic Article
|
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
|
|
Academic Article
|
Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile.
|
|
Academic Article
|
The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway.
|
|
Academic Article
|
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
|
|
Academic Article
|
Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.
|
|
Academic Article
|
Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.
|
|
Academic Article
|
Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.
|
|
Academic Article
|
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.
|
|
Academic Article
|
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.
|
|
Academic Article
|
Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration.
|
|
Academic Article
|
Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells.
|
|
Academic Article
|
Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
|
|
Academic Article
|
Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.
|
|
Academic Article
|
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.
|
|
Academic Article
|
Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice.
|